GlassScriptPhysician profile
William Earl Decker
NPI 1457349755
$4,145.54
in general payments reported to CMS, 2019-2025
33 companies · $736 in 2025
The $736 reported for 2025 was more than what 80% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,132 · 2020: $716 · 2021: $301 · 2022: $249 · 2023: $763 · 2024: $247 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.71 |
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,817.63 | 2019-2025 | Optune, Optune Gio |
| Gt Medical Technologies, INC | $393.04 | 2022-2025 | Gammatile, Gammatile |
| Novartis Pharmaceuticals Corporation | $254.35 | 2019-2025 | |
| Varian Medical Systems, INC. | $252.80 | 2019-2020 | |
| Amgen INC. | $247.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $239.26 | 2019-2025 | Imfinzi |
| Brainlab, INC. | $146.50 | 2024 | Surgical Planning and Navigation Radiation Treatment Planning and Positioning |
| Teleflex LLC | $129.02 | 2025 | Barrigel |
| Takeda Pharmaceuticals U.S.A., INC. | $72.21 | 2019-2020 | |
| Tersera Therapeutics LLC | $66.92 | 2019 | |
| Siemens Medical Solutions USA, INC. | $43.73 | 2019-2023 | Varian Identify |
| Ipsen Biopharmaceuticals, INC | $38.92 | 2019 | |
| Janssen Biotech, INC. | $38.46 | 2019-2020 | |
| Zap Surgical Systems, INC. | $34.53 | 2022 | |
| Telix Pharmaceuticals | $34.22 | 2023 | Illuccix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.23 | 2019-2024 | Jaypirca, Verzenio |
| Clovis Oncology, INC. | $31.02 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.98 | 2019 | |
| Csl Behring | $24.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.06 | 2025 | Adstiladrin |
| Genentech USA, INC. | $19.84 | 2019 | |
| Seagen INC. | $19.74 | 2019 | |
| Celgene Corporation | $18.52 | 2019 | |
| Taiho Oncology, INC. | $16.06 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.58 | 2019 | |
| Merck Sharp & Dohme LLC | $15.23 | 2019 | |
| Pfizer INC. | $14.88 | 2019 | |
| Kyowa Kirin, INC. | $14.78 | 2024 | Poteligeo |
| Smith+Nephew, INC. | $14.07 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $13.37 | 2019 | |
| Genzyme Corporation | $12.61 | 2019 | |
| Incyte Corporation | $12.30 | 2019 | |
| Tactile Systems Technology INC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.